

Date: 14th February, 2025

To,
The Manager,
Bombay Stock Exchange Limited,
Department of Corporate Services
P.J Towers, Dalal Street,
Mumbai 400001

Script Code: 540359

Sub: Outcome of Board Meeting

Dear Sir/Madam,

Pursuant to the provisions of Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the Company at its meeting held today, i.e. February 14, 2025 inter alia has considered and approved:

1. The Unaudited Financial Results of the Company for the quarter ended on December 31, 2024. The same has also been reviewed by the Audit Committee in its meeting held today.
2. B A Shah S R Mehta & Co., Statutory Auditors of the Company have carried out the Limited Review of the Unaudited Financial Results for the quarter December 31, 2024 and the Board has also taken on record their Limited Review Report on the said Results.

The Board Meeting commenced at 3:00 PM and concluded at 4:00 PM

You are requested to kindly take the above information on your record.

Thanking you.

For **Parmax Pharma Limited**

Bhakti

Bhakti Aghera
Company Secretary

End a/a

Statement of Standalone Unaudited Results for the Quarter & Nine Months ended 31.12.2024							(in Rs. Thousands)
Sr. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024
	(Refer Notes Below)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I.	Revenue from operations	62844.41	92774.88	13273.27	233782.30	67955.65	110530.35
II.	Other income	127.03	1165.23	109.48	1372.41	339.78	481.16
III.	Total Income (I+II)	62971.44	93940.12	13382.75	235154.70	68295.43	111011.50
IV.	Expenses						
	(a) Cost of materials consumed	49668.13	74361.19	5989.52	185768.36	22641.85	70292.73
	(b) Purchase of stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-4106.53	-315.19	254.32	-7507.43	15240.35	230.00
	(d) Employee benefits expense	8437.84	8212.15	8379.65	24134.85	24119.11	29107.93
	(e) Finance Costs	1064.05	1288.50	1561.61	3478.72	4591.30	6216.78
	(f) Depreciation and amortisation expense	4090.67	4033.60	4537.31	12086.51	13047.75	17116.70
	(g) Other expenses*	7762.45	8529.48	10188.16	23185.27	31656.04	44606.10
	Total expenses (IV)	66916.61	96109.73	30910.55	241146.28	111296.40	167570.25
V.	Profit/(Loss) from operations before exceptional items and tax (I-IV)	-3945.16	-2169.62	-17527.80	-5991.58	-43000.97	-56558.74
VI.	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0
VII.	Profit/ (Loss) before tax (V-VI)	-3945.16	-2169.62	-17527.80	-5991.58	-43000.97	-56558.74
VIII.	Tax expense:						
	(1) Current tax	0.00	0.00	0.00	0.00	0.00	0.00
	(2) Deferred tax	0.00	0.00	0.00	0.00	0.00	946.47
IX.	Net Profit / (Loss) for the period from continuing operations (VII-VIII)	-3945.16	-2169.62	-17527.80	-5991.58	-43000.97	-57505.22
X.	Profit/(loss) from discontinued operations				0.00	0.00	
XI.	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0
XII.	Profit/(loss) from Discontinued operations (after tax) (X-XI)	0.00	0.00	0.00	0.00	0.00	0
XIII.	Profit (Loss) for the period (IX+XII)	-3945.16	-2169.62	-17527.80	-5991.58	-43000.97	-57505.22
XIV.	Other Comprehensive Income						
	A. (i) Items that will not be reclassified to profit or loss						
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	B. (i) Items that will be reclassified to profit or loss						
	(ii) Income tax relating to items that will be reclassified to profit or loss						
XV.	Total Comprehensive Income for the period (XIII+XIV) Comprising Profit (Loss) and Other comprehensive Income for the period)	-3945.16	-2169.62	-17527.80	-5991.58	-43000.97	-57505.22
XVI.	Paid-up equity share capital (Face Value Rs 10)	37413.00	37413.00	37413.00	37413.00	37413.00	37413.00
XVII.	Earnings per share (for continuing operation & discontinuing operation) (of Rs. 10/- each):						
	(a) Basic	-1.05	-0.58	-4.68	-1.60	-11.49	-15.37
	(b) Diluted	0.00	0.00	0.00	0.00	0.00	0.00

PARMAX PHARMA LIMITED

Regd. Off. & Factory : Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. **Tel.:** Fac.+91-2827-270534 - 35 - 36 **e-mail :** info@parmaxpharma.com **CIN :** L24231GJ1994PLC023504

Correspondence Add.: A/1102, Bilipatra Apts., B/h. Balaji Hall, Nr. Dholakiya School, Off. 150 Ft. Ring Road, Nana Mauva, Rajkot - 360 004, Gujarat (INDIA)

Digitally signed by UMANG ALKESH GOSALIA
Date: 2025.02.14 15:45:55 +05'30'

Notes:

1. The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 14.02.2025
2. The Statutory Auditors have carried out a Limited Review of the Unaudited standalone results of the quarter and nine months ended 31st December, 2024
3. The Company is operating in single (pharmaceutical) segment, so above results are for single segment only.
4. Statement of Unaudited Financial Results of the company for the quarter and nine months ended 31st December, 2024, in the prescribed format under Schedule III of Companies Act, 2013
5. The figures for the previous period have been regrouped wherever necessary.

FOR, PARMAX PHARMA LIMITED

Digitally signed by UMANG
ALKESH GOSALIA
Date: 2025.02.14 15:43:38 +05'30'

Place Hadamtala (Rajkot)
Date: 14.02.2025

Dr. Umang Gosalia
Managing Director
DIN: 05153830

PARMAX PHARMA LIMITED

Regd. Off. & Factory : Plot No. 20, Survey No. 52, Rajkot-Gondal National Highway No. 27, Hadamtala, Tal. Kotda Sangani, Dist. Rajkot-360 311, Gujarat, INDIA. **Tel.:** Fac.+91-2827-270534 - 35 - 36 **e-mail :** info@parmaxpharma.com **CIN :** L24231GJ1994PLC023504

Correspondence Add.: A/1102, Bilipatra Apts., B/h. Balaji Hall, Nr. Dholakiya School, Off. 150 Ft. Ring Road, Nana Mauva, Rajkot – 360 004, Gujarat (INDIA)

B A SHAH S R MEHTA & Co.

Chartered Accountants

Partner
Malay B Shah
B.Com. F.C.A.
M. No. 159526

Partner
Zarna M Shah
M.Com. F.C.A. DISA
(Information Systems Audit)
M. No. 144246

Auditor's Limited Review Report On Unaudited Financial Results

The Board of Directors,

PARMAX PHARMA LIMITED

We have reviewed the accompanying statement of standalone unaudited financial results of **PARMAX PHARMA LTD** ("the Company") for the quarter and Nine months ended **31st December 2024** ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This Statement is the responsibility of the Company's management and has been approved by the Board of Directors on **14th February 2025**. Our responsibility is to issue a report on this Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



Head Office:
209-Sapphire Complex, IInd Floor
21/25-B New Jagnath Plot,
Dr.Yagnik Road
RAJKOT- 360 001
(GUJARAT)

Electronic Address:
(O) 0281-2468261

(M) 09427564149
(E) bassrmco.office@gmail.com
Or
mbshah_31@hotmail.com

B A SHAH S R MEHTA & Co.

Chartered Accountants

Partner
Malay B Shah
B.Com. F.C.A.
M. No. 159526

Partner
Zarna M Shah
M.Com. F.C.A. DISA
(Information Systems Audit)
M. No. 144246

Subject to our observation that company has incurred Expenses for repairs and replacement of Rs 35.71 Lakhs for Building and Rs 336.68 Lakhs for Plant and Machinerics due to damage on account of Fire took place in the month of December 23. Company is awaiting Surveyors Report, in absence of Surveyors Report Claim is not yet submitted with Insurance company.

Based on our review conducted except as above, nothing has come to our attention that causes us to believe that the accompanying statement of standalone unaudited financial results prepared in accordance with applicable accounting standards i.e. Indian Accounting Standards (IND AS) prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Rajkot

Date: 14.02.2025



For **B. A. SHAH S R MEHTA & Co.**
Chartered Accountants
FRN NO: 128796W

A handwritten signature in black ink that reads "Malay B. Shah".

MALAY B SHAH
Partner
M. No. 159526
UDIN: 25159526BMNYUR7631

Head Office:
209-Sapphire Complex, IInd Floor
21/25-B New Jagnath Plot,
Dr.Yagnik Road
RAJKOT- 360 001
(GUJARAT)

Electronic Address:
(O) 0281-2468261

(M) 09427564149
(E) bassrmco.office@gmail.com

Or

mbshah_31@hotmail.com